Alcoholic and Toxic Liver Disease
The liver is the organ responsible for concentrating and metabolizing most drugs and toxins. Because of this function, toxic insults to the liver are common. In the U.S., drug-induced liver injury is the most common cause of acute liver failure. Alcohol-related liver disease accounts for more than 12,000 deaths yearly in the U.S., and alcohol abuse is the most common cause of cirrhosis. Hospital admissions for alcoholic hepatitis are on the rise in the U.S., accounting for 0.83% of all admissions in 2010.
Alcohol is the most frequently abused drug worldwide. Its major metabolite, acetaldehyde, is directly toxic to the liver. Abuse results in a broad spectrum of liver disease, including asymptomatic fatty liver, alcoholic hepatitis, cirrhosis, and end-stage liver failure. Many people with alcohol use disorder become symptomatic only when severe, life-threatening liver disease is already present.
Virtually any drug can cause some degree of hepatotoxicity, although certain drugs are more toxic than others. In some cases (e.g., sulfonamides), substances are directly toxic to the liver. In others, liver damage occurs by immune-mediated hypersensitivity. Common drug classes with known hepatotoxicity include antidepressants, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs, including cyclooxygenase-2 inhibitors), muscle relaxants, psychotropics, anticonvulsants, lipid-lowering drugs (i.e., statins), oral antidiabetic agents, estrogens, anabolic steroids, anti-tuberculosis agents, antibiotics (most commonly amoxicillin-clavulanate and tetracycline), methyldopa, and methotrexate (when combined with alcohol). Some of these drugs have known and predictable hepatotoxicity (e.g., acetaminophen) whereas others result in idiosyncratic reactions (e.g., NSAIDs).
In high doses, vitamin A, arsenic, iron, and copper can be hepatotoxic. Additionally, iron can accumulate in patients with chronic liver disease, resulting in overload. Hepatotoxicity from use of herbal and dietary supplements accounts for about 20% of all cases of drug-induced liver injury and may be the most common serious adverse effect of herbal supplements. Known hepatotoxic herbs causing liver injury include certain ayurvedic herbs, black cohosh, kava, pennyroyal oil, ma huang (Ephedra sinica), valerian, mistletoe, comfrey, chaparral, sassafras, borage, and germander. Herb-induced liver injury is a diagnosis of exclusion as the clinical presentation is not specific and may be attributed to a variety of other conditions.
The presentation and severity of liver disease varies widely. Some patients remain asymptomatic despite significant liver damage, while others present with a severe, acute illness. Nausea, vomiting, malaise, and diaphoresis are common symptoms. A syndrome similar to viral hepatitis may occur, including fever, headache, jaundice, and right-upper-quadrant pain. Pruritus may occur if cholestasis develops. Abdominal distension may develop from ascites. Jaundice is a common presentation in people with alcoholic hepatitis. Hepatic encephalopathy and coagulopathies may develop in severe instances.
Because of the liver’s regenerative ability, withdrawal of or abstinence from offending substances can sometimes result in significant reversal of liver damage, even in cases of advanced liver disease, so long as cirrhosis is not yet established.
Alcohol use. Sustained alcohol intake exceeding 30 g per day (one standard alcoholic drink has 14 g) is associated with progression to cirrhosis and non-cirrhotic liver damage in both men and women. Binge drinking, drinking alcohol outside of mealtimes, and drinking beer or hard alcohol versus wine have all been associated with increased rates of liver damage.
Sex. Females have an increased risk of liver disease for a given amount and duration of alcohol use, and liver disease in women tends to progress more rapidly than in men.
Genetics. There appear to be genetic predispositions to alcohol abuse and alcoholic liver disease; however, specific genes have yet to be identified.
Viral hepatitis. Concurrent infection with hepatitis B virus or hepatitis C virus is strongly associated with risk of accelerated liver disease in alcoholic patients.
Malnutrition. Inadequate nutritional intake in chronic alcohol abusers may worsen the severity of liver disease.
Acetaminophen. Acetaminophen toxicity is greatly increased with the concomitant ingestion of alcohol.
Drug dosages. Toxicity due to medications is typically dose-related.
Nutritional supplements. High doses of preformed vitamin A can be hepatotoxic, as can certain botanicals. See Nutritional Considerations below.
The diagnosis of drug- and toxin-induced liver injury is often difficult. A detailed history and physical examination are essential and should include an investigation for accidental, environmental, and intentional exposures.
In patients with suspected herb-induced or drug-induced liver injury, the updated 2016 Roussel Uclaf Causality Assessment Method can be used. This tool provides two scales, one for hepatocellular injury and the other for cholestatic or mixed liver injury.
Liver Function Tests
Elevations of the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are common and signify hepatocellular injury. A ratio of AST-to-ALT greater than 2 suggests alcoholic hepatitis.
Elevation of alkaline phosphatase or bilirubin out of proportion to the aminotransferases suggests cholestasis.
Low albumin concentration along extended prothrombin time (due to impaired synthesis of coagulation factors, primarily factor VII) reflect impaired hepatic synthetic function.
Bilirubin can be elevated due to either hepatocellular injury or cholestasis.
In suspected cases of alcohol abuse, a careful history and screening with a validated screening tool such as the CAGE questions or AUDIT may be used to establish the diagnosis.
Hematologic abnormalities may be present in patients with alcoholic liver disease, including macrocytosis, leukocytosis, thrombocytopenia, and folate deficiency.
Liver biopsy is useful in ruling out viral hepatitis and other specific causes of liver disease, but it is often not diagnostic for drug-induced toxicity. Biopsy can grade the severity of toxic liver disease and exclude coexisting liver diseases, but it may not be necessary when the clinical presentation is clear (e.g., the chronic use of a single drug associated with hepatotoxicity).
Right-upper-quadrant ultrasound, abdominal X-ray, CT scan, MRI, and/or endoscopic retrograde cholangiopancreatography (ERCP) may be indicated to rule out other liver and abdominal pathology, such as cholecystitis, pancreatitis, and malignancy.
Suspected drugs or toxins should be discontinued immediately. Recovery often occurs after withdrawal of the offending substance.
Abstinence from alcohol is essential. Patients should be appropriately counseled on alcohol cessation, including referral to Alcoholics Anonymous, psychotherapy, or similar programs.
Acetaminophen overdose is treated with activated charcoal and n-acetylcysteine.
Other than treatment for acute acetaminophen toxicity, specific therapies are generally not available. In cases of hypersensitivity reactions (e.g., penicillin, procainamide) or alcoholic hepatitis, corticosteroids may be useful.
Supportive treatments in cases of liver failure include nutritional changes (see Nutritional Considerations below), vitamin K for coagulopathy, and correction of micronutrient deficiencies (e.g., folate). Secondary complications (e.g., hepatic encephalopathy) should be addressed as necessary.
Liver transplantation may be required in patients with severe acute liver failure or chronic liver disease.
Although vitamin A deficiency has been reported in both patients with hepatitis C-related chronic liver disease and in approximately 50% of patients with alcoholic cirrhosis, vitamin A supplements are potentially hepatotoxic. Daily intakes of > 25,000 IU for at least 6 years or > 100,000 IU for at least 6 months are thought to produce hepatotoxic effects. Steatosis, perisinusoidal fibrosis, chronic hepatitis, and cirrhosis may result from chronic over administration. Carotenoids are safer, providing vitamin A activity without the risks of vitamin A taken either in the form of food or supplements.
Niacin also has hepatotoxic potential, and this appears to be caused by both plain niacin and most (if not all) sustained-release preparations.
Some herbal supplements, particularly those from China and India, have been found to induce hepatoxicity as a result of improper extraction methods and contamination with heavy metals (mainly mercury, lead, arsenic, cadmium), among other causes. The addition of synthetic adulterants to herbal products is also a concerning issue.
Hepatotoxic effects have been noted for weight loss aids, including usnic acid, 1,3-dimethylamylamine (1,3-DMAA), conjugated linoleic acid (CLA), garcinia cambogia, ma huang (Ephedra), and Herbalife products that contain mixtures of herbs.
Raw forms of certain botanical supplements, including comfrey, are sources of hepatotoxic pyrrolizidine alkaloids; topical forms used for the treatment of painful muscle and joint complaints are very low in or free of these alkaloids.
Kava is a botanical used for anxiolytic effects. It was withdrawn from the market in several countries after cases of severe liver injury had been established, despite clinical trials that were unable to demonstrate hepatotoxicity and systematic reviews and meta-analyses that found a positive benefit-to-risk ratio for kava in treating anxiety disorders., The use of acetone-based extracts is thought to be responsible for hepatotoxic effects of kava preparations, as opposed to water-based extraction methods.
Certain over-the-counter herbal products (e.g., pennyroyal) cause hepatotoxicity by inhibition of CYP450 and depletion of glutathione; liver damage by other herbs (e.g., chaparral) may be due to contaminants or improperly prepared extracts.,
The above examples are by no means an exhaustive list. As the use of dietary supplements continues to grow, clinicians will be challenged with determining whether supplements are to blame for cases of liver injury, or if other causes (interaction with other supplements, medications, alcohol, past history of liver disease) are more likely.
Probiotic foods or supplements may be helpful for patients with alcohol-related hepatoxicity. In clinical trials with these patients, probiotics have been shown to reduce endotoxemia, improve liver function, and reduce the amount of microbe-derived lipopolysaccharide (LPS) that plays a key role in the pathophysiology of alcohol-related liver disease.
Patients with hepatoxicity, including those with alcohol-induced hepatotoxicity, have lower concentrations of branched-chain amino acids, such as leucine, isoleucine, and valine- a characteristic of the 3-4-fold increase of plasma amino acids in acute liver failure. A growing body of literature has demonstrated beneficial cerebral, metabolic, and nutritional effects of branched-chain amino acids in patients who have hepatic encephalopathy from hepatoxicity. The European Society for Clinical Nutrition and Metabolism’s updated 2018 guidelines recommend branched-chain-amino-acid-enriched formula for patients who develop hepatic encephalopathy during enteral nutrition.
See Basic Diet Orders chapter.
What to Tell the Family
Liver damage most often results from excessive habitual alcohol intake. It can also be caused by several prescription medications and over-the-counter supplements. The family can support patients by providing an environment that discourages excessive alcohol consumption, making sure medications are taken only as directed, and checking with qualified health care personnel, such as a physician and a pharmacist, before allowing the use of herbal and nutritional supplements.
- Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-72. [PMID:16317692]
- Crabb DW, Im GY, Szabo G, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. [PMID:31314133]
- Riley TR, Bhatti AM. Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise. Am Fam Physician. 2001;64(9):1555-60. [PMID:11730310]
- Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther. 2007;25(10):1135-51. [PMID:17451560]
- Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399-408. [PMID:25043597]
- Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845-50. [PMID:9462221]
- O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology. 2010;51(1):307-28. [PMID:20034030]
- Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015;17(1). [PMID:26712744]
- Bémeur C, Butterworth RF. Nutrition in the management of cirrhosis and its neurological complications. J Clin Exp Hepatol. 2014;4(2):141-50. [PMID:25755550]
- García-Cortés M, Robles-Díaz M, Ortega-Alonso A, et al. Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci. 2016;17(4):537. [PMID:27070596]
- Green AS, Fascetti AJ. Meeting the Vitamin A Requirement: The Efficacy and Importance of β-Carotene in Animal Species. ScientificWorldJournal. 2016;2016:7393620. [PMID:27833936]
- Knopp RH, Retzlaff BM, Fish B, et al. The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. J Clin Lipidol. 2009;3(3):167-178. [PMID:20046930]
- Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci. 2016;17:588-626.
- Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med. 2002;252(2):107-13. [PMID:12190885]
- Staiger C. Comfrey root: from tradition to modern clinical trials. Wien Med Wochenschr. 2013;163(3-4):58-64. [PMID:23224633]
- Pantano F, Tittarelli R, Mannocchi G, et al. Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat. Int J Mol Sci. 2016;17(4):580. [PMID:27092496]
- Chua HC, Christensen ET, Hoestgaard-Jensen K, et al. Kavain, the major constituent of the anxiolytic kava extract, potentiates GABA A r eceptors: functional characteristics and molecular mechanism. PLoS One. 2016;22:11:e0157700-e0157717.
- Whitton PA, Lau A, Salisbury A, et al. Kava lactones and the kava-kava controversy. Phytochemistry. 2003;64(3):673-9. [PMID:13679089]
- Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3-17. [PMID:23121117]
- National Library of Medicine. LiverTox: clinical and research information on drug-induced liver injury website. Available at: https://livertox.nih.gov/Chaparral.htm. Updated October 20, 2022. Accessed November 23, 2022.
- Sung H, Kim SW, Hong M, et al. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol. 2016;22(29):6673-82. [PMID:27547010]
- Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485-521. [PMID:30712783]